Crispr Therapeut Stock Price, News & Analysis

CRISPR Therapeutics (Nasdaq: CRSP) reported positive Phase 1 data for CTX310 on Nov 8, 2025, presented at AHA Scientific Sessions and published in NEJM. A single-course IV infusion produced dose-dependent, durable editing of ANGPTL3 with a mean reduction of -73% (max -89%). At the highest dose, mean triglycerides (TG) fell -55% (max -84%; mean -60% in patients with baseline TG >150 mg/dL) and mean LDL fell -49% (max -87%) by Day 60. CTX310 was generally well tolerated in 15 participants with no treatment-related serious adverse events and no ≥Grade 3 transaminase changes. CRISPR is advancing CTX310 into Phase 1b, prioritizing severe hypertriglyceridemia and mixed dyslipidemia.

CRISPR Therapeutics (NASDAQ: CRSP) reported preclinical CTX460 data using its SyNTase™ editing platform for Alpha-1 Antitrypsin Deficiency (AATD). Key results shown at ESGCT 2025 include >90% mRNA correction, a 5-fold increase in total serum AAT, and an >99% M-AAT:Z-AAT ratio in disease models after a single dose. Near-saturating hepatocyte editing occurred at doses as low as 0.1 mg/kg, with >90% mRNA correction at 0.5 mg/kg and durability of effect up to 7–9 weeks in rodent models.

CTX460 is formulated in a proprietary LNP and is expected to enter clinical testing in mid-2026, positioning the program as a potential best-in-class, mutation‑targeting approach for AATD.

Monash University, Australia's largest research institution, has announced the establishment of the Monash Boston Hub in Cambridge to strengthen its biotech partnerships in North America and Europe. The Hub will facilitate licensing, drug discovery, and clinical trial collaborations.

The university has completed over 160 license deals and created 30+ spinouts in the past five years, collectively raising nearly $1 billion. The new Hub, staffed by 5-7 professionals led by Nathan Elia, will be located at the Cambridge Innovation Center.

Notable partnerships include Moderna's mRNA manufacturing facility on Monash's campus and collaborations with CRISPR Therapeutics (NASDAQ: CRSP). The university's Monash Institute of Pharmaceutical Sciences (MIPS) has helped progress over 40 novel drug candidates into clinical development.

CRISPR Therapeutics (Nasdaq: CRSP) announced the upcoming presentation of its novel SyNTase gene editing technology at the ESGCT 2025 Annual Congress. The presentation will showcase preclinical data for treating Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disorder.

The SyNTase platform combines compact Cas9 proteins with engineered polymerases, achieving up to 95% editing efficiency in cell models with minimal off-target effects. In preclinical studies, a single intravenous dose (≤0.5 mg/kg) demonstrated high efficiency in humanized mouse models, while achieving >70% mRNA correction and >3-fold total serum AAT upregulation in humanized rat models of AATD.

The presentation is scheduled for October 10, 2025, at 11:00 a.m. CEST during the Gene Editing III session.

CRISPR Therapeutics (NASDAQ: CRSP) and Sirius Therapeutics have announced the dosing of the first patient in a Phase 2 clinical trial of SRSD107, their co-developed Factor XI (FXI) siRNA therapy for preventing venous thromboembolism in total knee arthroplasty patients.

SRSD107 demonstrated promising results in Phase 1 trials, showing over 93% reduction in FXI levels and a twofold increase in aPTT relative to baseline. The treatment's effects were sustained for up to six months post-dosing, suggesting potential for semi-annual administration.

The therapy aims to address limitations of current anticoagulants by reducing pathological thrombosis while minimizing bleeding risk. The addressable market includes patients with atrial fibrillation, VTE, cancer-associated thrombosis, and various cardiovascular conditions where bleeding risk currently limits treatment options.

CRISPR Therapeutics (Nasdaq: CRSP) announced it will present late-breaking data at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans, Louisiana, from November 7-10, 2025.

The company will showcase two key presentations: A late-breaking oral presentation on Phase 1 clinical data for CTX310™, their CRISPR/Cas9 gene editing therapy targeting ANGPTL3 for cardiovascular and cardiometabolic disease, and a poster presentation on CTX340™, their preclinical program targeting angiotensinogen for refractory hypertension treatment.

The presentations are scheduled for November 8, 2025, with the CTX310 data presented at 8:30 a.m. CST and the CTX340 poster at 2:30 p.m. CST. Presentation materials will be available on the company's website after the sessions.

CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company specializing in gene-based medicines, has announced its participation in two major investor conferences in September 2025.

The company will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8 at 4:30 p.m. ET and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9 at 8:30 a.m. ET. Live webcasts will be available on the company's website, with replays accessible for 14 days after the presentations.

CRISPR Therapeutics (NASDAQ:CRSP) reported its Q2 2025 financial results and business updates, highlighting significant progress across its commercial and clinical programs. The company's flagship product CASGEVY® has achieved its target of activating 75 authorized treatment centers globally, with ~115 patients completing cell collection and 29 receiving infusions.

Key clinical developments include CTX310™ showing promising preliminary data with up to 82% reduction in triglycerides and 86% in LDL, and ongoing trials for CTX112™ and CTX131™ in oncology and autoimmune diseases. The company maintains a strong financial position with $1.7 billion in cash and equivalents, despite reporting a net loss of $208.5 million for Q2 2025.

CRISPR Therapeutics (NASDAQ: CRSP) has been named to TIME's 100 Most Influential Companies list for 2025 in the Pioneers category. The recognition highlights the company's groundbreaking work in gene editing and its expansion beyond treating sickle cell disease and beta thalassemia into cardiovascular and autoimmune diseases.

The selection process involved TIME editors evaluating companies based on impact, innovation, ambition, and success, with input from global contributors, correspondents, and external experts. CEO Samarth Kulkarni emphasized the company's mission to transform medicine through science and innovation, viewing the recognition as validation of their team's dedication to advancing genetic medicine.